## Prediction of prostate cancer in patients with benign prostatic hyperplasia

Kogan M.I., Iliyash A.V., Chibichyan M.B., Shiranov K.A.

Rostov State Medical University, Department of Urology, Rostov-on-Don, Russia **INTRODUCTION & OBJECTIVES:** To develop formula for prediction of prostate cancer in patients with benign prostate hyperplasia (BPH), undergoing surgical treatment.

**MATERIAL & METODS:** 359 patients, undergoing surgical treatment of BPH were included in our study (mean age 66.7 y± 0.6 (range 41-88)). Diagnostic studies were prostate-specific antigen (PSA) assay (5.6±0.3(0.2-24) ng/ml), digital rectal investigation (DRI) (palpable induration was in 5.6%), transrectal ultrasound (TRUS) (mean prostate volume was 82.4. SD=2.6 (range 39-213) ml; hypoechogenic lesion was determined in 6.4% cases), morphological examination of bioptates and resected prostate tissue (prostate cancer was found in 23 patients (5.8%)). Discriminant analysis was performed, which allows to determine statistically significant diagnostic criteria for prostate cancer and standardized coefficients, and to develop formula on its basis to predict prostate cancer.

**RESULTS:** In patients with a suspicion of prostate cancer after performing standard diagnostic studies, who has already have biopsy negative results, diagnostic coefficient  $(C_d)$  should be calculated as follows:  $C_d = 9.01 - (9.62 \cdot x_1) - (0.015 \cdot x_2) - (0.27 \cdot x_3) - (9.51 \cdot (x_4: x_2))$ , where  $x_1$  is 0, when induration within prostate is present, while in cases with no induration,  $x_1$  is 1;  $x_2$  is prostate volume, ml;  $x_3$  is prostatic intraepithelial neoplasia (PIN) (in cases with high PIN  $x_3$  is 1, in cases without high PIN,  $x_3$  is 0);  $x_4$  is total PSA level, ng/ml.

In patients with no indications to prostate biopsy, it should be used the next formula:  $C_d = 6.14 - (0.18 \cdot x_1) - (3.19 \cdot x_2) + (7.66 \cdot x_3) + (140 \cdot (x_2 \cdot x_4)) + (0.09 \cdot x_4)$ , where  $x_1$  is patient age;  $x_2$  is total PSA level, ng/ml;  $x_3$  is free PSA level, ng/ml;  $x_4$  is prostate volume, ml.

In those cases, when  $C_d > 0$ , we confirm our diagnosis of BPH, while in cases, when  $C_d < 0$  we can suspect prostate cancer. Diagnostic sensitivity of this method is 77.7% and 78.6%, specificity is 93.4% and 96.3% for 1 and 2 formula, respectively (p<0.001).

**CONCLUSIONS:** Proposed formulas can predict prostate cancer prior to surgical treatment of BPH and optimize indications for prostate biopsy.